Common variable immunodeficiency (CVID), is a heterogeneous group of disorders charac terized by hypogammaglobulinemia associated with B cell, T cell, and dendritic cell defects (De Gast et al., 1980; Reinherz et al., 1981; Levy et al., 1998; CunninghamRundles and Bodian, 1999; Bonhomme et al., 2000; Cunningham Rundles et al., 2001; Bayry et al., 2004; Park et al., 2008; PaquinProulx et al., 2013b) . The clinical picture is characterized by recurrent bacterial infections predominantly caused by Streptococcus pneumoniae, Klebsiella pneumoniae, and Haemophilus influenzae (Van der Hilst et al., 2002; Park et al., 2008; Hong et al., 2010) . Sev eral genetic mutations associated with CVID have been identified only in 15-20% of CVID cases (Park et al., 2008) . In particular, mutations in the TNFRSF13B (TACI; Castigli et al., 2005) , ICOS (Grimbacher et al., 2003) , CD19 (van Zelm et al., 2006) , CD20 (Kuijpers et al., 2010) , and CD81 (van Zelm et al., 2010 ) genes have been previously described.
Hypogammaglobulinemia is defined by the plasmatic concentration of IgG <4.9 mg/ml, and the current treatment consists of intrave nous IgG (IVIG) replacement every 3-4 wk (CunninghamRundles, 2010) with the goal of protecting the patients against extracellular pathogen infections. Although protection against extracellular bacteria is commonly assigned to B cell responses with the production of high affinity antibodies, adequate CD4 T cell func tion is essential for optimal B cell maturation and antibody production, activation of macro phages, and/or recruitment of effector cells to the site of infection (Bloom and Bennett, 1970;  In the present study, we have investigated the functional profile of CD4 T cells from patients with common variable immunodeficiency (CVID), including production of cytokines and proliferation in response to bacteria and virus-derived antigens. We show that the functional impairment of CD4 T cells, including the reduced capacity to proliferate and to produce IFN- and IL-2, was restricted to bacteria-specific and not virus-specific CD4 T cells. High levels of endotoxins were found in the plasma of patients with CVID, suggesting that CD4 T cell dysfunction might be caused by bacterial translocation. Of note, endotoxemia was associated with significantly higher expression of programmed death 1 (PD-1) on CD4 T cells. The blockade of the PD-1-PD-L1/2 axis in vitro restored CD4 T cell proliferation capacity, thus indicating that PD-1 signaling negatively regulates CD4 T cell functions. Finally, we showed that intravenous immunoglobulin G (IVIG) treatment significantly reduced endotoxemia and the percentage of PD-1 + CD4 T cells, and restored bacteria-specific CD4 T cell cytokine production and proliferation. In conclusion, the present study demonstrates that the CD4 T cell exhaustion and functional impairment observed in CVID patients is associated with bacterial translocation and that IVIG treatment resolves bacterial translocation and restores CD4 T cell functions. levels of programmed death 1 (PD1) molecule. In addition, the blockade of the PD1-PD ligand 1/2 (PDL1/2) pathway was associated with the restoration of bacteriaspecific CD4 T cell proliferation, thus demonstrating that the functional impairment of bacteriaspecific CD4 T cells was caused by PD1-associated cell exhaustion. Of note, we also showed that all untreated CVID patients have detectable levels of endotox ins, i.e., a marker of bacterial translocation, and that endotox emia inversely correlated with IgG concentration. Finally, longitudinal analyses of CVID patients demonstrated that IVIG treatment significantly reduced endotoxemia and PD1 expres sion on CD4 T cells, and restored bacteriaspecific CD4 T cell cytokine production and proliferation. The present study pro vides new insights in the mechanisms responsible for the CD4 T cell functional impairment in CVID patients and indicates that IVIG treatment results in resolution of bacterial transloca tion and restoration of CD4 T cell functions.
RESULTS

Bacteria-specific CD4 T cells from CVID patients are functionally impaired
In the present study, 26 CVID patients and 30 healthy individ uals have been enrolled (Tables 1 and 2 ). It is important to David, 1973; Nathan et al., 1983; Ishihara et al., 1986; Parker, 1993; Ye et al., 2001; McHeyzerWilliams and McHeyzer Williams, 2005) . Several CD4 T cell abnormalities have been documented in CVID patients (Sneller and Strober, 1990; Aukrust et al., 1994; CunninghamRundles and Bodian, 1999; Giovannetti et al., 2007) and include the reduction of CD4 T cell count, inversion of CD4/CD8 ratio, and func tional alterations such as reduced proliferation capacity and/or impaired production of cytokines (Sneller and Strober, 1990; Aukrust et al., 1994; CunninghamRundles and Bodian, 1999; Giovannetti et al., 2007) . However, the causes of the CD4 T cell functional impairment remains unknown.
In the present study, we hypothesized that the recurrent bacterial infections occurring in CVID patients may lead to secondary CD4 T cell deficiency. To test this hypothesis, we have performed a comprehensive investigation of the func tional profile of CD4 T cells including the capacity to produce cytokines, such as TNF, IFN, IL2, and IL17A, and/or to proliferate in response to bacteria and virusderived antigens.
We demonstrate that bacteriaspecific but not virusspecific CD4 T cells were impaired in both their capacity to produce IFN and IL2 and to proliferate. Interestingly, bacteria specific but not virusspecific CD4 T cells expressed higher Ar ticle
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CD4 T cells were significantly reduced in CVID patients as compared with healthy individuals (P = 0.0006 and P = 0.003, respectively; Fig. 1 C and not depicted). However, the frequencies of both bacteriaspecific and virusspecific CD4 T cells producing TNF were not significantly different between the two groups (P = 0.6841 and P = 0.8202, re spectively; Fig. 1 C) , and only a trend toward lower fre quency of bacteriaspecific CD4 T cells producing IL17A was observed in CVID patients (P = 0.2413; Fig. 1 C) . Of note, the capacity of bacteriaspecific CD4 T cells to pro duce IL4 or IL21 was also evaluated by flow cytometry. The frequencies of IL4-or IL21-producing bacteria specific CD4 T cells were very low and not significantly different between CVID patients and healthy subjects (P = 0.3950 and P = 0.8714, respectively; data not shown). The proliferation capacity of bacteriaspecific but not virus specific CD4 T cells was also significantly reduced (P < 0.0001 and P = 0.8745, respectively) in CVID patients as compared with healthy subjects (Fig. 1, D and E), thus demonstrating that bacteriaspecific CD4 T cells of CVID patients are selectively dysfunctional. It is also important to mention that no differences be tween the cytokine profile or the proliferation profile of S. pneumoniae/K. pneumoniae and S. aureus and E. coli were ob served (unpublished data). The absence of difference in the underscore that none of the CVID patients investigated in the present study for phenotypic and functional analyses and for the measures of endotoxins in plasma had documented active bacterial infections at the time of blood collection. In this re gard, C reactive protein (CRP) was measured in 18 patients at the time of the study. CRP levels were <10 mg/liter (cutoff of the method in the central laboratory of the hospital) in 17 out of 18 patients and slightly positive, i.e., 11.5 mg/liter, in one patient.
To evaluate the functional profile of bacteriaspecific and virusspecific CD4 T cells of CVID patients, blood mononu clear cells of CVID patients (n = 12) and healthy individuals (used as control; n = 30) were stimulated with bacteria derived antigens from Staphylococcus aureus, S. pneumoniae, Streptococcus agalactiae (i.e., group B Streptococcus), Pseudomonas aeruginosa, K. pneumoniae, and two serotypes of Escherichia coli or virusderived antigens (Ad5 and CMV), and cytokine pro duction and proliferation capacity were analyzed by multipa rametric flow cytometry.
Representative flow cytometry profiles for S. pneumoniae and K. pneumoniae in one healthy donor and one CVID pa tient are shown in Fig. 1 (A and B) . The cumulative data for all the bacteria and virusspecific CD4 T cell responses mentioned above showed that the frequencies of IFN-and IL2-producing bacteriaspecific but not virusspecific 
Detection of endotoxins in plasma of CVID patients
We postulated that the CD4 T cell dysfunction observed in CVID patients could be related to bacterial translocation. To test this hypothesis, bacterial translocation was evaluated using an enzymatic reaction detecting the presence of endotoxins in virusspecific T cell responses between CVID patients and healthy controls is consistent with the lack of clinical evi dence of increased reactivation of chronic virus infections in CVID patients (CunninghamRundles and Bodian, 1999; Raeiszadeh et al., 2006) . P-values were calculated using Student's t test. *, P < 0.05; **, P < 0.001; ***, P < 0.0001.
both the plasma of CVID patients with serum levels of IgGs <4.9 mg/ml (n = 8) and in healthy individuals (n = 10; Roger et al., 2009) . All CVID patients with serum IgG levels <4.9 mg/ml had measurable levels of endotoxin, whereas en dotoxin was not detected in healthy controls (0%; P < 0.0001; Fig. 2 A) . Consistent with this, the levels of endotoxin were sig nificantly higher in CVID patients with IgG levels <4.9 mg/ml as compared with healthy subjects (P = 0.0027; Fig. 2 B) .
Therefore, these results demonstrate the occurrence of bacte rial translocation in CVID patients with low serum IgG levels.
Increased PD-1 expression on CD4 T cells of CVID patients
On the basis of the occurrence of microbial translocation and the observed selective dysfunction of bacteriaspecific CD4 T cells, we speculated that the functional impairment of bacteriaspecific CD4 T cells might result from the modulation of the expression of coinhibitory molecules (Barber et al., 2006; Day et al., 2006; Petrovas et al., 2006; Trautmann et al., 2006; McMahan et al., 2010) . We therefore evaluated the expres sion of PD1, 2B4, CD160, signaling lymphocytic activation molecule (SLAM), CTLA4, LAG3, and TIM3 on CD4 T cells (HS, n = 10; CVID patients, n = 9). P-values were calculated using either one-way ANOVA (Kruskal-Wallis test) or Student's t test for multiple comparisons. *, P < 0.05; **, P < 0.001; ***, P < 0.0001.
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T cells of CVID patients (n = 21) and healthy subjects (n = 30) by flow cytometry. CD4 T cells of CVID patients expressed significantly higher levels of PD1 as compared with healthy subjects (P < 0.0001; Fig. 3, A and B) . No significant differ ences were observed in the expression of 2B4, CD160, SLAM, CTLA4, LAG3, and TIM3 (P > 0.05; Fig. 3 , A and B). Morita et al. (2011) showed that blood PD1 + CXCR5 + CD4 T cells shared functional properties with germinal cen ter T follicular helper (Tfh) cells, i.e., IL21 production and induction of Ig production from autologous B cells. There fore, the expression of CXCR5 and PD1 was evaluated in memory (CD45RA  ) CD4 T cell populations of CVID pa tients and healthy subjects to determine whether increased PD1 expression was associated with CXCR5 expression. As shown in the cumulative data (Fig. 3 C) , the frequencies of PD1 + CXCR5 + CD4 T cell populations were not signifi cantly different between CVID patients and healthy individuals (P = 0.2704). These data demonstrate that the increased ex pression of PD1 in memory CD4 T cells observed in CVID patients is not associated with CXCR5 expression, thus indi cating that blood Tfhlike cell populations are not increased in CVID patients.
T cell dysfunction may also result from skewed T cell dif ferentiation or immunosenescence (Champagne et al., 2001; Deeks et al., 2012) . T cell differentiation (based on CCR7 and CD45RA expression; Sallusto et al., 1999) and immunosenes cence (based on CD57 expression; Petrovas et al., 2006) markers were then investigated. No significant differences were observed in the frequency of central memory (CD45RA  CCR7 + ), effector memory (CD45RA  CCR7  ), and terminally differ entiated effector memory (CD45RA + CCR7  ) CD4 T cells P-values were calculated using paired Student's t test. *, P < 0.05.
PD1-PDL1/2 signaling restored the proliferation of bacteria specific CD4 T cells in CVID patients at levels comparable to healthy subjects (P > 0.05). (Fig. 3 D) , and in that of CD57expressing CD4 T cells between CVID patients and healthy subjects (P > 0.05; Fig. 3 E) . A trend toward a skewed effector memory phenotype was observed only in three CVID patients. Because increased PD1 expression may also be associated with T cell activation (Cellerai et al., 2010) , the expression of activation markers, such as CD69, CD25, and HLADR, was assessed by flow cytometry but no significant differences were observed in the expression of these markers between CVID patients and healthy subjects (P > 0.05; Fig. 3 F) .
As shown above, CD4 T cell dysfunction was found to be restricted to bacteriaspecific CD4 T cells. It was then impor tant to determine whether the increased PD1 expression was also predominantly restricted to bacteriaspecific CD4 T cells. To assess and to compare the expression of PD1 in bacteria and virusspecific CD4 T cells, we took advantage of a re cently described flow cytometry-based technique by Haney et al. (2011) which allows the identification and characteriza tion of antigenspecific CD4 T cells on the basis of the ex pression of membrane TNF (mTNF). Levels of PD1 were significantly higher in bacteriaspecific but not virusspecific CD4 T cells in CVID patients as compared with healthy sub jects (P < 0.0001; Fig. 4, A and B) . In addition, the percentage of PD1-expressing total CD4 T cells directly correlated with the percentage of PD1-expressing bacteriaspecific CD4 T cells (r = 0.9543, P < 0.0001; Fig. 4 C) . Collectively, these results indicate that the selective dysfunction of bacteria specific CD4 T cells results from the increased expression of the negative regulatory receptor PD1 which is likely driven by microbial translocation.
PD-1 blockade restores bacteria-specific CD4 T cell proliferation PDL1 and PDL2 are the ligands to PD1 and are ex pressed on different cell types (Ito et al., 2007) . PDL1 is expressed on hematopoietic and nonhematopoietic cells, whereas PDL2 is expressed on DCs and macrophages (Ito et al., 2007) . To delineate the involvement of PD1-PDL1/2 signaling in the impaired proliferation of bacteriaspecific CD4 T cells, blood mononuclear cells of CVID patients (n = 10) were labeled with CFSE and stimulated with bacteria or virusderived antigens in the presence or in the absence of anti-PDL1/2 blocking antibodies or isotype controls (Petrovas et al., 2006; Trautmann et al., 2006; Yamamoto et al., 2011) . The frequency of proliferating CD4 T cells (CD3 + CD4 + CFSE low cells) was assessed at day 6. Representative flow cytometry profiles (Fig. 5 A) and cumulative data (Fig. 5 B) showed that the blockade of PD1-PDL1/2 signaling sig nificantly increased bacteriaspecific-and also, to a lower extent, virusspecific-CD4 T cell proliferation (1.83fold increase, P = 0.0024, and 1.07fold increase, P = 0.0396, respectively; Fig. 5 , B and C), supporting the involvement of PD1-PDL1/2 signaling as the primary cause of the im paired bacteriaspecific CD4 T cell proliferation. Isotype control treatment did not have any effect on virusspecific CD4 T cell proliferation capacity. Of note, the blockade of Figure 6 . PD-1 expression directly influences CD4 T cell cytokine profile in CVID patients. Blood mononuclear cells from CVID patients (n = 12) were stimulated with bacteria antigen preparations and cytokine production (IL-17A, IL-2, TNF, and IFN-) by CD4 T cells from CVID patients with low frequency (<30%; white circles) or high frequency (>30%; black circles) of PD-1 expression was assessed by polychromatic flow cytometry. (A) Proportion of bacteria-specific CD4 T cells producing TNF, IFN-, IL-2, and/or IL-17A. All the possible combinations of the responses are shown on the x axis and the percentage of the functionally distinct cell populations within the bacteria-specific CD4 T cell populations are shown on the y axis. The pie chart summarizes the data, and each slice corresponds to the fraction of CD4 T cells with a given number of functions within the responding CD4 T cell population. Statistical analyses of the global cytokine profiles (pie charts) were performed by partial permutation tests using the SPICE software as previously described (Roederer et al., 2011) . Bars correspond to the fractions of different functionally distinct T cell populations within the total CD4 T cells. Red stars indicate statistical significance (*, P < 0.05) calculated using a Student's t test. levels of PD1 (<30%) were significantly more polyfunctional (produced TNF, IFN, and IL2; P = 0.003; Fig. 6 A) . Interest ingly, the proportion of triple TNF/IFN/IL2, dual IFN/ IL2, and dual TNF/IL2 was significantly increased at the ex pense of single TNFproducing CD4 T cell populations in bacteriaspecific CD4 T cell responses of CVID patients with PD1-expressing CD4 T cells <30% as compared with those with PD1 expression >30% (P < 0.05; Fig. 6 A) . Finally, the proportion of IL2-producing bacteriaspecific CD4 T cells negatively correlated with the frequency of PD1-expressing CD4 T cells (r = 0.7060, P = 0.0041; Fig. 6 B) .
PD-1 expression influences CD4 T cell cytokine profile
We then tested whether PD1 expression on CD4 T cells may influence the CD4 T cell cytokine profile in CVID patients. In this regard, the cytokine profile of bacteriaspecific CD4 T cells was correlated with PD1 expression. The qualitative differ ences in the cytokine profile of bacteriaspecific CD4 T cells on the basis of PD1 expression are shown in Fig. 6 . The cu mulative data showed that the cytokine profile of bacteria specific CD4 T cells expressing higher levels of PD1 (>30%) was skewed toward single TNFproducing bacteriaspecific CD4 T cells, whereas bacteriaspecific CD4 T cells expressing lower on CD4 T cells was also significantly reduced after 11 mo of IVIG treatment (P = 0.008; Fig. 7 G) . Finally, we showed that the PD1 expression level in CD4 T cells inversely correlated with the percentage of bacteriaspecific CD4 T cell prolifera tion (r = 0.7345, P = 0.0011; Fig. 7 D) . Collectively these data demonstrate that IVIG treatment induces resolution of bacterial translocations in the large majority of patients and re stores CD4 T cell proliferation.
DISCUSSION
In the present study, we have hypothesized that recurrent bacterial infections observed in CVID patients were responsi ble for the CD4 T cell impairment and we postulated that the CD4 T cell dysfunction was predominantly restricted to bacteriaspecific CD4 T cells. In this regard, the clinical picture of CVID patients is complicated by recurrent bacterial infec tions (Van der Hilst et al., 2002; Park et al., 2008; Hong et al., 2010) , whereas no increase in the frequencies of acute (i.e., influenza) or reactivation of chronic viral infections (i.e., EBV or CMV; Raeiszadeh et al., 2006) has been reported.
Our results indicate that the impairment of CD4 T cell functions was selective to bacteriaspecific but not virus specific T cell responses. CD4 T cells from CVID patients had reduced capacities to produce cytokines (IL2 and IFN) and to proliferate. The defect in the production of IL2 may be responsible for the defects of T cell proliferation described in CVID patients together with the exhaustion associated with the PD1 expression. The defect in the production of IFN may not necessarily be responsible for the direct impairment of CD4 T cells but for the defective bactericidal activity of macrophages through the defective activation of macrophages by impaired Th1 CD4 T cells from CVID pa tients. Of note, no significant differences were observed in CD4 T cell differentiation, immunosenescence, and activa tion markers between CVID patients and healthy individuals in our cohort of patients. An increase in the proportion of activation markers has been recently reported in CD4 T cells of CVID patients (PaquinProulx et al., 2013a) .
The severe impairment in CD4 T cell function found in CVID patients was reminiscent of that observed in patients with HIV infection (Day et al., 2006; Petrovas et al., 2006; Trautmann et al., 2006) . The CD4 T cell dysfunction in HIV infection has been at least partially attributed to the chronic immune stimulation resulting from microbial translocation (Brenchley et al., 2004; Brenchley and Douek, 2008) . We therefore investigated the presence of microbial translocation in CVID patients through the determination of endotoxemia levels. Interestingly, we found increased endotoxemia levels in patients with CVID which inversely correlated with IgG serum levels. The continuous leak of bacteria in the gut and bronchial mucosa might be responsible for the exhaustion of bacteriaspecific CD4 T cells. In support of our hypothesis, CD4 T cells of CVID patients showed significant increased expression of PD1 as compared with healthy individuals. We also provided evidence that PD1 was selectively in creased in bacteriaspecific CD4 T cells, as indicated by the Effective IVIG treatment restores the CD4 T cell functional impairment As shown above, the detection of endotoxemia was observed in CVID patients with hypogammaglobulinemia. On the basis of these findings, we have determined the correlation between endotoxemia and IgG serum levels, and the effects of Ig replacement therapy on endotoxemia and, in turn, on CD4 T cell functions. We show that endotoxemia inversely correlated with the serum levels of IgG (r = 0.5988, P < 0.0001; Fig. 7 A) . With regard to serum IgA levels, we did not find any correlation between serum IgA levels and endo toxemia (r = 0.066 and P = 0.6930). Furthermore, with re gard to the frequencies of B cell populations in the CVID patients (we have used the Euro class definition; Wehr et al., 2008) , no association was observed between the proportion of CD27 + B cells (or any other B cell population) and endo toxemia (unpublished data). Finally, endotoxemia did not correlate with inflammatory bowel diseases (Table 2) .
Furthermore, the presence of endotoxin was assessed in CVID patients (n = 8) before and after IVIG therapy. The IgG titers consistently increased >4.9 mg/ml after IVIG ther apy (Fig. 7 B) . Endotoxemia levels consistently and signifi cantly decreased after initiation of therapy, suggesting that IVIG therapy was associated with efficient reduction of bac terial translocation in CVID patients (P = 0.0437; Fig. 7 B) . IVIG therapy might potentially influence endotoxemia levels through the presence of antiLPS IgG antibodies. To exclude the potential impact of antiLPS antibodies in the detection/ concentration of LPS, we determined the effects of treating in vitro the serum of an untreated CVID patient positive for the detection of LPS with IVIG at a final IgG concentration of 10 mg/ml. A CVID patient with low LPS levels, i.e., 53 pg/ml, was selected to have the best experimental conditions to detect any potential interference of the IVIG treatment. Of note, serum treatment with IVIGs did not significantly reduce LPS concentration (P = 0.7802; unpublished data). These data indicate that IVIG treatment is unlikely to influ ence the detection of LPS in the sera of CVID patients.
We then investigated the effects of continuous IVIG ther apy in restoring normal CD4 T cell function. To address this issue, PD1 expression on bacteriaspecific CD4 T cells was assessed in blood mononuclear cells of IVIGtreated CVID pa tients (n = 6) at two time points (spaced by 8.8 mo on average). Representative flow cytometry profiles and cumulative data showed that IVIG treatment significantly reduced PD1 ex pression on bacteriaspecific CD4 T cells (P = 0.0120; Fig. 7 , C and D). In addition, the proliferation capacity of bacteria specific CD4 T cells was assessed in blood mononuclear cells of IVIGtreated CVID patients (n = 8) at two time points (spaced by 11.2 mo on average). Representative flow cytome try profiles and cumulative data showed that IVIG treatment significantly restored bacteriaspecific CD4 T cell proliferation (P = 0.0165; Fig. 7, E and F) . Of note, IVIG therapy restored the proliferation of bacteriaspecific CD4 T cells in CVID pa tients at levels comparable to healthy subjects (P > 0.05; un published data). In addition, the percentage of PD1 expression 2042 CD4 T cell exhaustion in CVID patients | Perreau et al.
>7 mg/ml. Whether the dose of Ig replacement should be in creased to achieve higher IgG serum levels in CVID patients has been debated (CunninghamRundles, 2010) . One could speculate that higher IgG concentration may be beneficial to CVID patients by reducing the bacterial infections and likely by reducing the general degree of inflammation. In support of this assumption, it has been recently shown that highdose therapy of IVIG (range 1-3 g/kg) leads to antiinflammatory effects via FcRIImediated IL33 production by dendritic cells that induces IL4 secretion by basophils and promotes antiinflammatory (Th2) responses (Anthony et al., 2011) . In conclusion, the present study provides new insights in the mechanisms responsible for the CD4 T cell impairment pres ent in patients with CVID and has identified endotoxemia as a novel marker to monitor the therapeutic response to Igs transcomplementation.
MATERIALS AND METHODS
Study groups.
In the present study, 26 CVID patients (Table 1) and 30 healthy individuals have been enrolled. Blood samples from the healthy subjects were obtained from the Blood Bank of Lausanne, Switzerland. CVID patients were either recruited at the Centre Hospitalier Universitaire Vaudois (Lausanne, Switzerland) or at the Hôpital HenriMondor Albert Chenevier (Paris, France). The Institutional Review Boards of both institu tions approved this study and informed consent was obtained from each individual enrolled. The diagnosis of CVID was formulated according to the European Society for ImmunoDeficiencies (ESID) and PanAmerican Group for Immunodeficiency (PAGID) criteria. The clinical manifestations of CVID include predominantly recurrent bacterial infections, noninfec tious lung and digestive pathologies, autoimmune diseases, and increased susceptibility to cancers ( Table 2 ). The medical records of the patients stud ied were analyzed to determine the clinical symptoms before the diagnosis of CVID. Most patients suffered from recurrent bacterial infections several years before the diagnosis of CVID was confirmed. All patients suffered from recurrent sinusitis and antibiotic therapy was administered several times per year. Recurrent lower respiratory tract infections (bronchitis and pneumonia) were present in 19 out of 26 patients. One patient experienced bacterial meningitis. Gastrointestinal complaints were identified in 3 pa tients, mainly recurrent diffuse abdominal pain and diarrhea. An intestinal parasite (Strongyloides stercoralis) was found in 1 patient. 7 out of 26 patients had autoimmune manifestations, 16 out 26 patients had intestinal lymphoid hyperplasia, and 4 out of 26 granulomatosis disease.
Cell isolation. Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll gradient (GE Healthcare). After centrifugation (300 g, 20 min), PBMC ring was harvested in PBSEDTA 2 mM (Laboratorium Dr Bichsel AG, and Ambion for PBS and EDTA, respectively). Cells were either used directly or cryopreserved in liquid nitrogen for future experiments. Further demonstration that the expression of PD1 was the primary cause of the exhaustion and of the associated func tional impairment of bacteriaspecific CD4 T cells was ob tained by the finding that restoration of proliferation occurred after the blockade of PD1-PDL1 axis.
Levels of endotoxin inversely correlated with IgG serum levels, thus indicating that hypogammaglobulinemia was poten tially responsible for microbial translocation (Brenchley et al., 2004; Brenchley and Douek, 2008) and increased endotoxemia in CVID patients. This hypothesis was supported by the finding that IVIG treatment induced the reduction of endotoxemia.
CVID patients were also longitudinally followed up to determine whether IVIG treatment had any impact on the restoration of CD4 T cell functions. Interestingly, IVIG treat ment was associated with lower PD1 expression and restoration of polyfunctional cytokine responses, and increased prolifera tion in response to stimulation with bacteriaderived anti gens. No more differences in the percentage of proliferating bacteriaspecific CD4 T cells were observed between healthy subjects and CVID patients after treatment with antiPDL antibodies in vitro and IVIG therapy.
Collectively, the results on the relationship between IgG levels and endotoxemia and the impact of IVIG therapy on the levels of endotoxemia indicate that endotoxemia may be instru mental to monitor the response to therapy in CVID patients. Because suppression of endotoxemia is also associated with the improvement of bacteriaspecific CD4 T cell functions, the measure of endotoxemia may also serve as an indirect marker of restoration of bacteriaspecific CD4 T cell functions.
Our results favor the following model that is not exclu sive of CVID but likely applicable to any pathological condi tion causing Ig deficiency. Recurrent bacterial infections in CVID patients result from defective levels of IgA in the mucosa and of IgG that circulates and passively diffuses through the oropharyngeal or gut mucosa (Butcher et al., 1975; Lieberman et al., 1979; Coruh and Mason, 1980; Morris et al., 1980; Brandtzaeg et al., 1985) . Ig deficiency is associ ated with microbial translocation, which causes selective ex haustion of bacteriaspecific CD4 T cells as indicated by the upregulation of the coinhibitory receptor PD1 in these cells. In turn, PD1-expressing bacteriaspecific CD4 T cells show reduced proliferation capacity and defective production of cytokines (IL2 and IFN). The treatment with IVIG re stores bacteriaspecific CD4 T cell responses, likely due to the reduction of bacteriaderived antigen load which, in turn, results in reduction of the magnitude of chronic stimulation and PD1 expression on bacteriaspecific CD4 T cells. The restoration of CD4 T cell functions is consistent with the similar effects observed in chronic viral infections, such as HIV or hepatitis C virus, after suppression of viral load with antiviral therapy (Day et al., 2006; Trautmann et al., 2006) .
The current recommendation of IgG transcomplementation is to reach plasmatic IgG serum levels of 6 mg/ml by admin istering 400 mg/kg Igs every 3-4 wk (Orange et al., 2006) . More than 95% of healthy individuals have IgG serum levels Flow cytometry. Data were acquired on an LSR SORP with four lasers (405, 488, 532, and 633 nm; BD), analyzed using FlowJo (version 9.4.11; Tree Star). When required SPICE software (version 5.21; developed by M. Roederer, National Institutes of Health) was used (Roederer et al., 2011) . At least 100,000 events were acquired for each sample.
Antigens preparation. S. aureus, S. pneumoniae, S. agalactiae, P. aeruginosa, K. pneumoniae, and the two serotypes of E. coli were grown in tryptic soy broth (BD) at 37°C, washed, and heatinactivated by incubation for 2 h at 56°C as previously described (Perreau et al., 2012) .
Assessment of CD4 T cell cytokine profile. Freshly isolated blood mononuclear cells (10 6 cells) were stimulated overnight as previously de scribed (Perreau et al., 2012) in complete RPMI medium (10% FCS, 100 U/ml penicillin, and 100 µg/ml streptomycin [Bioconcept] ). Blood mononuclear cells were stimulated with 1 µg/ml Ad5 vector or CMV lysat (Advanced Bio technologies INC) or 5 × 10 7 CFU/ml of individual bacteria or bacteria pool depending on the experiment. As a positive control, cells were stimulated with antiCD3/antiCD28 beads (Invitrogen). Cells were incubated for 18 h in 1 ml of complete media containing 1 µl/ml brefeldin A (Golgiplug; BD). At the end of the stimulation period, dead cells were stained (4°C, 15 min) using the violet LIVE/DEAD stain kit (Invitrogen). Cells were washed, per meabilized (Cytofix/Cytoperm solution; BD), and stained (4°C, 15 min) with anti-CD3APCH7, anti-CD4ECD, anti-CD8PerCP, anti-IFN AF700, anti-IL17AAF647, anti-TNFPECY7, and anti-IL2PE as pre viously described (Perreau et al., 2012) . Frequencies of cytokineproducing CD4 T cells were assessed by flow cytometry.
Assessment of CD4 T cell proliferation. Mononuclear cells were resus pended at 10 6 /ml in PBS and incubated for 7 min at 37°C with 0.25 µM 5, 6CFSE (Invitrogen) as previously described (Perreau et al., 2011) . The re action was quenched with one volume of fetal calf serum (FBS; Institut de Biotechnologies Jacques Boy). Subsequently, cells were washed and cultured in 4% human AB serum (Institut de Biotechnologies Jacques Boy) RPMI (Gibco; Life Technologies). Cells were stimulated with virusderived anti gens (Ad5 or CMV) or bacteriaderived antigens (either individual bacteria or bacteria pool depending on the experiment), with Staphylococcus entero toxin B (SEB, SigmaAldrich) as positive control, or remained unstimulated (negative control). After 6 d of in vitro T cell expansion, dead cells were stained (4°C, 15 min) using the violet LIVE/DEAD stain kit (Invitrogen), and cells were stained (4°C, 15 min) with anti-CD3APCH7, anti-CD4 ECD, and anti-CD8PerCP. Frequencies of proliferating CD4 T cells were assessed by flow cytometry.
Restoration of CD4 T cells proliferation.
CFSElabeled PBMCs were stimulated with virusderived antigens (Ad5 or CMV; 1 µg/ml), bacteria pool (5 × 10 7 CFU/ml), SEB as positive control, or unstimulated cells as negative control, in the presence or in the absence of 10 µg/ml PDL1/2 (eBioscience) as previously described (Trautmann et al., 2006) . After 6 d of stimulation, cells were washed and stained with violet LIVE/DEAD stain kit (4°C, 15 min). Cells were stained (4°C, 15 min) with anti-CD3APCH7, anti-CD4ECD, and anti-CD8PerCPCy5.5 and analyzed by flow cytometry.
Assessment of co-inhibitory molecule expression, T cell activation, T cell differentiation, and immunosenescence. PBMCs were resus pended (10 6 cells/ml and per condition) in complete RPMI medium. Dead cells were stained using the amcyan LIVE/DEAD stain kit (Life Technolo gies; 4°C, 15 min). Cells were washed and stained (4°C, 15 min) with panels of monoclonal antibodies to measure the expression of coinhibitory mole cules (anti-CD3APC H7, anti-CD4PB, anti-CD8Efluor625NC, anti2B4PeCY5.5, anti-CD160APC, anti-PD1PeCy7, and anti-SLAMPE),
